Optimal Intertemporal Curative Drug Expenses: The Case of Hepatitis C in France

Thierry Magnac and Pierre Dubois

No 23-1402, TSE Working Papers from Toulouse School of Economics (TSE)

Abstract: We study intertemporal trade-offs that health authorities (HAs) face when considering the control of an epidemy using innovative curative medical treatments. We set up a dynamically controlled Susceptibles-Infected-Recovered (SIR) model for an epidemy in which patients can be asymptomatic, and we analyze in a simple model, the optimality conditions of the sequence of cure expenses decided by HAs at the onset of the drug innovation. We show that analytical conclusions are ambiguous because of their dependence on parameter values. As an application, we focus on the case-study of Hepatitis C whose treatment underwent a major up-heaval when curative drugs were introduced in 2014. We calibrate our controlled SIR model using French data and simulate optimal policies. We show that the optimal policy entails some front loading of the intertemporal budget compared to fixed annual ones. The analysis demonstrates how beneficial the intertemporal budgeting can be compared to non forward looking constant budget allocation.

Keywords: pharmacy; SIR model; controlled epidemy dynamics; optimal intertemporal poli-; cies; hepatitis C (search for similar items in EconPapers)
JEL-codes: I12 I18 (search for similar items in EconPapers)
Date: 2023-01-25
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.tse-fr.eu/sites/default/files/TSE/docu ... 2023/wp_tse_1402.pdf Version 2023 (application/pdf)
https://www.tse-fr.eu/sites/default/files/TSE/docu ... version_jan_2024.pdf Revised Version 2024 (application/pdf)

Related works:
Journal Article: Optimal intertemporal curative drug expenses: The case of hepatitis C in France (2024)
Working Paper: Optimal Intertemporal Curative Drug Expenses: The Case of Hepatitis C in France (2024)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:tse:wpaper:127775

Access Statistics for this paper

More papers in TSE Working Papers from Toulouse School of Economics (TSE) Contact information at EDIRC.
Bibliographic data for series maintained by ().